Phase II Study of Carfilzomib in Patients With Refractory Renal Cell Carcinoma.

[1]  W. Kaelin.  The von Hippel–Lindau Tumor Suppressor Protein , 2018 .

[2]  R. Lauer,et al.  Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma. , 2015, The Oncologist.

[3]  K. Hess,et al.  Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab , 2014, Oncotarget.

[4]  G. Mills,et al.  Genetic and pharmacological strategies to refunctionalize the von Hippel Lindau R167Q mutant protein. , 2014, Cancer research.

[5]  G. Mills,et al.  Agents That Stabilize Mutated von Hippel–Lindau (VHL) Protein , 2012, Journal of biomolecular screening.

[6]  H. Moch,et al.  VHL gene mutations and their effects on hypoxia inducible factor HIFα: identification of potential driver and passenger mutations. , 2011, Cancer research.

[7]  A. Stewart,et al.  Carfilzomib: a novel second-generation proteasome inhibitor. , 2011, Future oncology.

[8]  S. Demo,et al.  Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. , 2007, Cancer research.

[9]  R. Motzer,et al.  Medullary renal cell carcinoma and response to therapy with bortezomib. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  C. Taylor,et al.  Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. , 2006, Cancer research.

[11]  Peter F Thall,et al.  Monitoring event times in early phase clinical trials: some practical issues , 2005, Clinical trials.

[12]  L. Schwartz,et al.  Phase II trial of bortezomib for patients with advanced renal cell carcinoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Thall,et al.  Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.

[14]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[15]  H. Goldschmidt,et al.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. , 2016, The Lancet. Oncology.

[16]  E. Vokes,et al.  Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.